Gestational Hypertension Management
Definition and Diagnosis
- The American College of Cardiology defines gestational hypertension as blood pressure ≥140/90 mmHg that appears after 20 weeks of gestation and generally resolves within 42 days postpartum 3
- Approximately one quarter of gestational hypertension cases progress to preeclampsia, especially those diagnosed before 34 weeks of gestation 1
- Diagnosis should be based on at least two elevated blood pressure readings on separate occasions 3
Blood Pressure Control
- Blood pressure ≥160/110 mmHg requires urgent treatment in a monitored setting; acceptable agents include oral nifedipine, labetalol, or intravenous hydralazine 4, 5
- For blood pressures consistently ≥140/90 mmHg in the clinic (or ≥135/85 mmHg at home), treatment is recommended with a goal diastolic pressure of 85 mmHg and systolic pressure between 110-140 mmHg 4, 2
- First-line acceptable agents include methyldopa, labetalol, oxprenolol, and nifedipine 4, 2
Maternal Monitoring
- Regular clinical evaluation, including assessment for clonus 1, 6
- Urine analysis at each visit to detect proteinuria 1
- Laboratory tests (hemoglobin, platelet count, liver enzymes, uric acid, and creatinine) at least at 28 and 34 weeks of gestation 1
Fetal Monitoring
- Evaluation of fetal well-being with ultrasound from 26 weeks of gestation 1, 2
- Subsequent evaluations every 2-4 weeks if fetal biometry is normal 1
- More frequent monitoring in the presence of suspected fetal growth restriction 1, 2
Indications for Hospitalization
- Development of preeclampsia 1
- Severe hypertension ≥160/110 mmHg 1, 6
- Neurological signs or symptoms 5
- Laboratory test abnormalities suggesting disease progression 6, 7
Delivery Planning
- Delivery can be delayed until 39+6 weeks if blood pressure can be controlled, fetal monitoring is reassuring, and preeclampsia has not developed 1, 2
- A large retrospective study concluded that the optimal time for delivery is between 38-39 weeks, but this needs clarification with future randomized trials 1
Pharmacological Considerations
- No relevant facts without [ignore ref] material.
Prevention of Adverse Outcomes
- No relevant facts without [ignore ref] material or from 'Praxis Medical Insights'.